---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-050607"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-07-29T20:07:19+00:00"
generated_at: "2026-07-29T20:08:15.177098+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B

## Summary
- Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.
- Lifyorli (relacorilant) generated $47.6M in first quarter of availability; over 1,300 patients started treatment.
- FY2026 revenue guidance increased to $1.1-1.2 billion.
- NDA for relacorilant in Cushing's syndrome resubmitted; PDUFA date December 17, 2026.
- Cash and investments $544.6M at June 30, 2026, up from $515.4M at March 31, 2026.

## SEC filing metadata
- accession: 0001628280-26-050607
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-07-29T20:07:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/0001628280-26-050607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-050607
- JSON: https://secwatch.observer/filing/0001628280-26-050607.json
- Plain text: https://secwatch.observer/filing/0001628280-26-050607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.